pSivida to Present at the 2017 BIO CEO & Investor
Post# of 301275
WATERTOWN, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug products, announced today that Nancy Lurker, President and Chief Executive Officer, is scheduled to present an overview of the company and its progress at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 8:00 a.m. ET. The conference will be held in New York, NY.
A live audio and/or webcast and subsequent archived replay of pSivida’s presentation may be accessed via the Investors section of the Company’s website under “Resources - Events & Presentations” at www.psivida.com . The replay will be available for 90 days after the event.
About pSivida Corp .
pSivida Corp. ( www.psivida.com ), headquartered in Watertown, MA, is a leader in the development of sustained release drug for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN ® , a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the US and three EU countries. Retisert ® , an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis being independently developed, is currently in pivotal Phase 3 clinical trials. pSivida's pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat uveitis, wet and dry age-related macular degeneration, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter , LinkedIn , Facebook and Google+ .
Contact: EVC Group Michael Polyviou/Doug Sherk – Investors mpolyviou@evcgroup.com; dsherk@evcgroup.com 212.850.6020; 646-445-4800 Thomas Gibson – Media tom@tomgibsoncommunications.com 201-476-0322
(0)
(0)